I-Qode Digital Solutions

🔬 From Science to Strategy: Haemophilia Gene Therapy GVD in 6 Months

When a leading biopharma firm approached us to develop a Global Value Dossier (GVD) for their gene therapy in Haemophilia, we knew the stakes were high.

Gene therapy isn’t just innovation — it challenges traditional payer models, especially in rare diseases.

But we don’t just write.
We co-create outcomes.

---

💼 Project Snapshot
🕒 Duration: 6 months
👥 Team:
- 1 HEOR / Market Access Expert
- 2 Medical Writers
- 1 Scientific Reviewer
- 1 Project Manager

🎯 Focus:

1. Value narrative

2. Cost-offset + budget impact

3. Payer-focused storytelling

4. Global affiliate alignment

---

🤝 Client Collaboration Highlights
We worked shoulder-to-shoulder with:

1. Global Value Leads

2. Regulatory & Clinical Teams

3. KOLs & Regional Stakeholders

Multiple workshops. Zero silos.
Every section reflected both clinical depth and access readiness.

---

✅ The Result?
A value-rich, globally adaptable GVD—ready for HTA, AMCP, and internal teams.

💬 “Your team brought science and strategy together. Seamless collaboration throughout.”
— Client, Market Access Strategy Lead

---

If you’re launching in a complex, high-value therapy area — let’s talk.

📩 DM us to see how we help turn science into global value.

📩 [email protected]
🌐 www.i-qode.com

---